USPTO-FDA study reinforces the need to protect pharmaceutical intellectual property rights for the future of new drug development.

The Inflation Reduction Act creates instability in the Medicare Part D Program.

The Inflation Reduction Act will ultimately raise drug costs and reduce future cures.

A new report challenges assertions made during the committee's recent hearing on the role of pharmacy benefit managers.

The FTC fails to acknowledge the benefits of pharmacy benefit managers and wrong blames them for high drug prices.

Title V of H.R. 8371 would slow deployments and improvements to the VA electronic health record management system. 

A federal flavor ban is clearly unpopular and would create black markets.

Pre-market application requirements for THR products injure public health and finances.